actinic keratosis

Type: Keyphrase
Name: actinic keratosis
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

Harsh UV rays take warmth out of sunny days this rainy season

PUNE: Sun rays beating down the city have been particularly harsh in the last two months. The sunny days in the months of July and August may have given city commuters a little respite from the rain, but the Indian Institute of Tropical Meteorology (IITM) ... [Published Times of India - Aug 23 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 2 reports

Biofrontera confident ahead of FDA meeting on Ameluz

Biofrontera ( LON:B8F ) has been scheduled a meeting with the US Food and Drug Administration ahead of its filing key products Ameluz and BF-RhodoLED for approval.   The pre-NDA meeting, set for 8 October, represents the last opportunity to obtain ... [Published Proactiveinvestors United Kingdom RSS feed - Aug 21 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Biofrontera AG: Belixos® now available through Amazon in Germany and UK

Prof. Hermann Lübbert, Chief Executive Officer of Biofrontera commented: "The UK is the first country outside Germany in which we have made our Belixos® products available. Amazon provides a perfect platform to offer these products to a wide group of ... [Published InfoStor - Aug 18 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

International dermatology company Galderma confirmed as multi million dollar buyer of sandalwood oil

The world's largest producer of Indian sandalwood says Nestle-owned company Galderma is the multi-million-dollar buyer of its oil.Tropical Forestry Services (TFS) announced in March it had signed a deal expected to be worth half a billion dollars with ... [Published ABC Online - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Global Non-melanoma Skin Cancer Market 2014-2018

NEW YORKAbout Non-melanoma Skin CancerNon-melanoma skin cancer is one of the most common types of cancer in the world. It develops in the upper layers of the skin, but not in melanocytes. There are two types of non-melanoma skin cancer: BCC, which starts ... [Published Bio-Medicine - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 2 reports

Biofrontera's Ameluz passes first stage approval in Israel

StockMarketWire.com - Biofrontera's Ameluz - a prescription drug for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy) - has passed its first stage approval in Israel. Biofrontera said ... [Published Stock Market Wire - Aug 11 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 4 reports

Biofrontera makes first Ameluz sales in Slovenia

Biofrontera (LON:B8F, ETR:B8F) has recorded the first sales of its prescription drug Ameluz in Slovenia, its maiden revenues from a Central Eastern European country.Ameluz is a topical treatment that tackles actinic keratosis (AK), a very comm...Related ... [Published BioPortfolio - Aug 06 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Meda Buys Rottapharm for $3.1B

Meda said today it will buy Rottapharm Madaus for SEK 21.2 billion (about $3.1 billion) from Italy’s Rovati family, in a deal the buyer said reflected its desire to grow into a leading specialty pharma through acquisitions—namely by combining the seller’s ... [Published Genetic Engineering News - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Quiz: Blister in the sun

A 53-year-old Caucasian male with a background of haemochromatosis, fatty liver disease and actinic keratosis presented with a one-year history of vesicles and bullae (see figure 1 right).These blisters initially developed on his hands but subsequently ... [Published Australian Doctor - Jul 30 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 3 reports

Kinex announces allowance of IND application for KX2-391 ointment by USFDA

Kinex Pharmaceuticals has announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the ... [Published PBR - News - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

Dr. K: Treatments rarely leave scars

Dr. Anthony L. Komaroff Dr. Anthony L. Komaroff Wednesday, July 23, 2014 0 Comments | Q I saw my doctor about a patch of rough, brown skin that I noticed on my upper arm. He said it is actinic keratosis and needs to be removed. Is it cancer? How will ... [Published Reflector.com - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Collagen for use in the treatment of skin diseases

The invention relates to collagen for use in the treatment of inflammatory and degenerative skin diseases and damage to the skin connected therewith, such as in particular in the treatment of psoriasis, dermatitis, neurodermitis, rosacea, urticaria (hives), ... [Published Free Patents Online - Jul 22 2014]

Quotes

"Using established methodology and best available estimates on UV-related mortality and morbidity, this report estimates that annually around 1.5 million DALYs (Disability-adjusted life years) are lost through excessive UV exposure globally. The report gives region, age and sex-specific estimates and includes detailed methodological considerations" added Parkhi
Hermann Luebbert, Biofrontera ’s chief executive, said: "We are looking forward to the opportunity to discuss our dossier for the combination of Ameluz and BF-RhodoLED with the FDA.  "
Hermann Luebbert, CEO of Biofrontera commented: "We are looking forward to the opportunity to discuss our dossier for the combination of Ameluz® and BF-RhodoLED® with the FDA. Since we have addressed all requests that the FDA had in the last meeting, we are confident that our data package will now satisfy all the requirements for filing. Whilst we had hoped for an earlier meeting, this delay will not influence the rest of our time table of filing the final dossier by the end of Q1 2015." Biofrontera AG
Prof. Hermann Lübbert, Chief Executive Officer of Biofrontera commented: "The UK is the first country outside Germany in which we have made our Belixos® products available. Amazon provides a perfect platform to offer these products to a wide group of people seeking care for itching or inflamed skin. We advise everybody who experiences itching after a mosquito bite or due to eczema, or who has a sunburn, to give Belixos® Crème a chance." Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs...

More Content

All (35) | News (32) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Harsh UV rays take warmth out of sunny days thi... [Published Times of India - Aug 23 2014]
Biofrontera confident ahead of FDA meeting on A... [Published Proactiveinvestors United Kingdom RSS feed - Aug 21 2014]
Biofrontera AG : FDA pre-New Drug Application m... [Published Investegate - Aug 21 2014]
Biofrontera pre-NDA meeting with FDA scheduled [Published Stock Market Wire - Aug 21 2014]
Biofrontera AG: Belixos® now available through ... [Published InfoStor - Aug 18 2014]
Forum Post: RE: Need help with my mole [Published Macmillan Cancer Support - Aug 16 2014]
International dermatology company Galderma conf... [Published ABC Online - Aug 15 2014]
What is squamous cell carcinoma? [Published Orthopedics Today - Aug 13 2014]
Global Non-melanoma Skin Cancer Market 2014-2018 [Published Bio-Medicine - Aug 13 2014]
Biofrontera's Ameluz passes first stage approva... [Published Stock Market Wire - Aug 11 2014]
Biofrontera eyes regulatory clearances for skin... [Published Proactive Investors.co.uk - Aug 11 2014]
MicroRNA-31 Is Overexpressed in Cutaneous Squam... [Published Plosone.org - Aug 06 2014]
Biofrontera makes first Ameluz sales in Slovenia [Published BioPortfolio - Aug 06 2014]
Biofrontera makes first Ameluz sales in Slovenia [Published Proactive Investors.co.uk - Aug 06 2014]
Biofrontera's Ameluz on sale in Slovenia [Published MoneyAM - Aug 06 2014]
Biofrontera AG: First Ameluz® sales in Central ... [Published Nasdaq - Aug 06 2014]
Swier Clinic announces opening of Skin Center [Published Cape Gazette - Aug 05 2014]
PhotoMedex to Hold Second Quarter 2014 Conferen... [Published Good Day Sacramento - Aug 04 2014]
Meda Buys Rottapharm for $3.1B [Published Genetic Engineering News - Jul 31 2014]
What Your Hands Can Reveal About Your Health [Published Huffington Post - Jul 31 2014]
House Calls: On skin cancer [Published Paris Express - Jul 30 2014]
Quiz: Blister in the sun [Published Australian Doctor - Jul 30 2014]
Kinex announces allowance of IND application fo... [Published PBR - News - Jul 25 2014]
Kinex receives FDA approval to begin Phase I st... [Published News-Medical.Net - Jul 25 2014]
Kinex Pharmaceuticals Announces Allowance of th... [Published PR Newswire: Health - Jul 24 2014]
Dr. K: Treatments rarely leave scars [Published Reflector.com - Jul 23 2014]
Treatments for actinic keratosis rarely leave s... [Published Park Hills Daily Journal - Jul 23 2014]
Collagen for use in the treatment of skin diseases [Published Free Patents Online - Jul 22 2014]
What Your Hands Reveal About Your Health [Published Grandparents Magazine - Jul 21 2014]
Biofrontera one of a rare breed of junior biotechs [Published Proactive Investors.co.uk - Jul 21 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Kinex announces allowance of IND application fo... [Published PBR - News - Jul 25 2014]
Kinex Pharmaceuticals has announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the ...
Kinex Pharmaceuticals Announces Allowance of th... [Published PR Newswire: Health - Jul 24 2014]
BUFFALO, N.Y., July 24, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third ...
Research and Markets: Actinic Keratosis Pipelin... [Published Business Wire Health News - Jul 01 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/smn5g3/actinic_keratosis) has announced the addition of the "Actinic Keratosis Pipeline Highlights - 2014 Update" report to their offering. The latest report Actinic ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.